Catalog No.: PC-35463Not For Human Use, Lab Use Only.
CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.
CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.
CKD-519 (Rocacetrapib) exhibites a maximum of 70%-86% inhibition of CETP activity and 25%-48% increase of HDL-C levels after two weeks of oral administration of 1, 3, or 10 mg/kg in transgenic mice expressing human CETP/apolipoprotein AI.
CKD-519 (Rocacetrapib, CKD519) is being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.
1. Kim CO, et al. Drug Des Devel Ther. 2016 Nov 15;10:3763-3770. eCollection 2016.
2. Lee S. Abstract 11228: a novel and potent CETP inhibitor, CKD-519 exerts strong HDL increment and anti-atherosclerotic effects. Circulation. 2013;128(Suppl 22):A11228.
